Hormone therapy is often used in association with chemotherapy in the
treatment of estrogen-responsive breast cancers. By using breast adeno
carcinoma cell lines, we show that antiestrogen treatment leads to a d
ramatic decrease of p53 protein levels. This effect leads to a loss of
wild-type p53 response to genotoxic treatment. This inhibition is ass
essed by the lack of p53 protein accumulation and the loss of the p53-
dependent induction of p21(WAF1/CIP1) expression. Given that the effec
ts of several anticancer agents are mediated through DNA damage, these
observations suggest that antiestrogen treatment could modulate cellu
lar response to chemotherapeutic agents.